Mukka Proteins Allots 2 Crore Warrants Worth ₹47 Crore to Non-Promoters
Mukka Proteins Limited approved the allotment of 2 crore convertible warrants to 15 non-promoter investors. The issue price is ₹23.50 per warrant, totaling ₹47 crore. Warrants are convertible into equity shares within 18 months upon payment of the balance issue price.
The allotment of warrants is a significant fundraising event that can impact the company's capital structure and future equity dilution, warranting a medium impact.
The company has successfully raised capital through the preferential allotment of warrants, which indicates positive financial activity and potential for growth.
Mukka Proteins Limited has announced the allotment of 2,00,00,000 (Two Crore) Convertible Warrants on a preferential basis to identified persons belonging to the Non-Promoter Category. The issue price for each warrant is ₹23.50, aggregating to a total of ₹47,00,00,000 (Rupees Forty-Seven Crores Only).
The allotment was approved by the Board of Directors via a resolution passed by circulation on September 09, 2026, following a special resolution passed through postal ballot on July 12, 2026, and receipt of in-principle approvals from BSE Limited and National Stock Exchange of India Limited.
Upon receipt of 25% of the issue price, being an upfront subscription amount of ₹5.88 per warrant, these warrants have been allotted. Each convertible warrant grants the holder the right to subscribe to one fully paid-up Equity Share of the company, with a face value of ₹1 each, upon payment of the remaining 75% of the issue price. This conversion option is exercisable within 18 months from the date of allotment, as per the SEBI ICDR Regulations. The warrants and the equity shares arising from their conversion will be subject to specified lock-in requirements.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.